title: EFNS guidelines on management of narcolepsy.
abstract: Management of narcolepsy with or without cataplexy relies on several classes of drugs, namely stimulants for excessive daytime sleepiness and irresistible episodes of sleep, antidepressants for cataplexy and hypnosedative drugs for disturbed nocturnal sleep. In addition, behavioral measures can be of notable value. Guidelines on the management of narcolepsy have already been published. However contemporary guidelines are necessary given the growing use of modafinil to treat excessive daytime sleepiness in Europe within the last 5-10 years, and the decreasing need for amphetamines and amphetamine-like stimulants; the extensive use of new antidepressants in the treatment of cataplexy, apart from consistent randomized placebo-controlled clinical trials; and the present re-emergence of gamma-hydroxybutyrate under the name sodium oxybate, as a treatment of all major symptoms of narcolepsy. A task force composed of the leading specialists of narcolepsy in Europe has been appointed. This task force conducted an extensive review of pharmacological and behavioral trials available in the literature. All trials were analyzed according to their class evidence. Recommendations concerning the treatment of each single symptom of narcolepsy as well as general recommendations were made. Modafinil is the first-line pharmacological treatment of excessive daytime sleepiness and irresistible episodes of sleep in association with behavioral measures. However, based on several large randomized controlled trials showing the activity of sodium oxybate, not only on cataplexy but also on excessive daytime sleepiness and irresistible episodes of sleep, there is a growing practice in the USA to use it for the later indications. Given the availability of modafinil and methylphenidate, and the forseen registration of sodium oxybate for narcolepsy (including excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep) in Europe, the place of other compounds will become fairly limited. Since its recent registration cataplexy sodium oxybate has now become the first-line treatment of cataplexy. Second-line treatments are antidepressants, either tricyclics or newer antidepressants, the later being increasingly used these past years despite few or no randomized placebo-controlled clinical trials. As for disturbed nocturnal sleep the best option is still hypnotics until sodium oxybate is registered for narcolepsy. The treatments used for narcolepsy, either pharmacological or behavioral, are diverse. However the quality of the published clinical evidences supporting them varies widely and studies comparing the efficacy of different substances are lacking. Several treatments are used on an empirical basis, specially antidepressants for cataplexy, due to the fact that these medications are already used widely in depressed patients, leaving little motivation from the manufacturers to investigate efficacy in relatively rare indications. Others, in particular the more recently developed substances, such as modafinil or sodium oxybate, are evaluated in large randomized placebo-controlled trials. Our objective was to reinforce the use of those drugs evaluated in randomized placebo-controlled trials and to reach a consensus, as much as possible, on the use of other available medications.
authors.affiliation: School of Medicine, University of Montpellier, Montpellier, France. mbilliard@wanadoo.fr
authors.forename: M
authors.initials: M
authors.lastname: Billiard
authors.forename: C
authors.initials: C
authors.lastname: Bassetti
authors.forename: Y
authors.initials: Y
authors.lastname: Dauvilliers
authors.forename: L
authors.initials: L
authors.lastname: Dolenc-Groselj
authors.forename: G J
authors.initials: GJ
authors.lastname: Lammers
authors.forename: G
authors.initials: G
authors.lastname: Mayer
authors.forename: T
authors.initials: T
authors.lastname: Pollmächer
authors.forename: P
authors.initials: P
authors.lastname: Reading
authors.forename: K
authors.initials: K
authors.lastname: Sonka
mesh_terms: D026683:Advisory Committees / Q000592:standards*; D000928:Antidepressive Agents / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000627:therapeutic use; D002375:Catalepsy / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D019468:Disease Management; D005060:Europe; D006801:Humans; D000077408:Modafinil; D009290:Narcolepsy / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D012978:Sodium Oxybate / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D012978:Sodium Oxybate; D000077408:Modafinil